沙美特罗／丙酸氟替卡松治疗儿童中重度哮喘的疗效观察

Observation on efficacy of salmeterol/fluticasone propionate in treatment of childred with moderate or serious asthma

目的观察吸入沙美特罗／丙酸氟替卡松干粉剂治疗儿童中重度哮喘的疗效及安全性。方法对153例中重度哮喘儿童采用沙美特罗／丙酸氟替卡松干粉剂吸入治疗，观察治疗前、治疗后第2、4、12周患儿日、夜哮喘症状严重程度并计分，记录每天需吸入短效β2受体激动剂的剂量和次数、哮鸣音改善情况；比较治疗前、治疗12周后PEF值或FEV1值。结果经吸入沙美特罗／丙酸氟替卡松治疗，第2、4、12周后患儿日、夜哮喘症状分值、吸入短效β2受体激动剂（特布他林）的剂量和次数明显减少，差异有显著意义（P〈0．05）；哮鸣音逐渐减少，直至消失；第12周时PEF／预计值或FEV1／预计值的百分比明显提高，差异有极显著意义（P〈0．01）。不良反应发生率为6．0％，反应轻微。结论沙美特罗／丙酸氟替卡松干粉剂治疗儿童中重度哮喘有疗效显著、安全的特点。

Objective To evaluate the effects and safety of Salmeterol/Fluticasone Propionate Powder inhalation on children with moderate or serious asthma. Methods 153 children with moderate or serious asthma were treated with inhalation of the Salmeterol/Fluticasone Propionate Powder. Scores of the asthma symptoms in daytime and the night before the treatment and 2weeks, 4weeks, 12weeks after the treatment were noted, and the duration of 2-receptor agonist such as rerbutaline sulfate use and use of puffs, as well as ausculated wheezing improvement were recorded, At the same time all children were measured for PEF or FEV1 before the treatment and 12 weeks after the treatment. Results Scores of asthma symptoms in daytime and the night、 albuterol sulfate use puffs of 2 weeks, 4 weeks and 12 weeks after the treatment were improved, significantly different from the pre-treatment levels （P〈0.01）, and also the wheezing improve gradually with the treatment time increased, and also the wheezing improve gradually till it disappeared completely. PEF/Pre% or FEV1/Pre% were significantly different between pre-treatment and 12 weeks after the treatment （P〈0.01）. drug-related adverse event rate was 6.0%, all of them were slight. Conclusion Inhalation of the Salmeterol/Fluticasone Propionate Powder is effective and safe for children with moderate or serious asthma.